Background: The present review is aimed to evaluate the correlation between pathological features and the response to steroid in the patients with IgA nephropathy according to the Oxford classification, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S), tubular atrophy and interstitial fibrosis (T).
Methods: We searched Chinese Biomedical Database, EMBASE, Cochrane Library, PubMed and MEDLINE with all spellings of "IgA nephropathy", "Oxford Classification", and "steroid".
Results: 5 studies with 637 patients were eligible for inclusion. The analysis showed that M1, S1, and T1/2 was strongly associated with the prediction to steroid resistance when compared with M0 [odds ratio (OR) 1.89, 95% confidence interval () 1.01 - 3.56, < 0.05], S0 (OR 2.24, 95% 0.99 - 5.08, = 0.05) and T0 (OR 2.16, 95% 1.29 - 3.63, = 0.004) respectively. There is no difference in steroid sensitivity between E0 and E1 ( = 0.55). The pooled OR of steroid resistance for E1 versus T1/2 is 0.50 ( = 0.04).
Conclusion: IgA nephropathy patients with serious pathological changes (M1, S1, and T1/2) were more resistant to steroid than slight ones (M0, S0, and T0), and E1 is better response to steroid therapy than T1/2.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601774 | PMC |
| http://dx.doi.org/10.18632/oncotarget.19574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.
Clin Kidney J
January 2025
Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Stuttgart, Germany.
Background: Sparsentan, a dual-acting antagonist for both the angiotensin II receptor type 1 and the endothelin receptor type A, has emerged as a promising therapeutic agent for the treatment of IgA nephropathy (IgAN). Following the publication of the PROTECT trial, sparsentan recently received approval for the treatment of IgAN in Europe. However, it remains uncertain whether an additive effect can be observed in the context of existing treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors, given that the PROTECT study did not investigate this dual therapy approach.
View Article and Find Full Text PDFMesangial C1q Deposition in IgA Nephropathy: Does the Classical Complement Pathway Play an Independent Role?
Indian J Nephrol
October 2024
UOC Nefrologia Dialisi e Trapianto, IRCCS Istituto Giannina Gaslini, Largo Gerolamo Gaslini, Genova, Italy.
Fibrillary Glomerulonephritis with Prevalent IgA Deposition Associated with Psoriasis.
Indian J Nephrol
August 2023
Department of Nephrology, Zydus Hospital, Ahmedabad, Gujarat, India.
Fibrillary and immunotactoid glomerulonephritis represent the pathological entities characterized by structured fibrillary/microtubular deposits, whose identification is possible only by electron microscopy. We report a 46-year-old female who presented with proteinuria 15 years after the onset of psoriasis. Diffuse global glomerulosclerosis pattern was noted on light microscopy.
View Article and Find Full Text PDFRenal limited sarcoidosis presenting with acute kidney injury.
Med J Armed Forces India
July 2023
Resident (Nephrology), Army Hospital (R&R), Delhi Cantt, India.
Sarcoidosis is a multisystem granulomatous disease of unknown etiology, characterized by noncaseating epithelioid granuloma, multinucleate giant cells, and tissue destruction. While lung and lymph node involvement is common, isolated renal involvement is rare. We report the case of a 55-year-old female patient, with renal limited sarcoidosis, who presented with worsening sensorium and acute kidney injury.
View Article and Find Full Text PDFIntroduction Nephrotic syndrome, an unusual clinical presentation of IgA nephropathy (IgAN), occurs only in a few cases. The data regarding its clinical characteristics and treatment outcomes are lacking. Material and methods In this retrospective analysis, we reviewed kidney biopsies conducted between January 2007 and December 2018.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!